Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma

Journal of Clinical Laboratory Analysis

Volumn 29, Issue 6, 2015, Pages 480-484

  Kan, Hiromi ^a   Yamagishi, Sho ichi ^b   Ojima, Ayako ^b   Fukami, Kei ^b   Ueda, Seiji ^b   Takeuchi, Masayoshi ^c   Hyogo, Hideyuki ^a   Aikata, Hiroshi ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGE; NASH; Non B or non C hepatocellular carcinoma

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR MARKER;

ADULT; AGE; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PROGNOSIS;

AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 84954318925     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21797     Document Type: Article

References (43)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Takuma Y, Nouso K, Makino Y, et al. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol 2011;26:1417-1424.
4. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 2012;204:300-307.
5. Akahoshi H, Taura N, Ichikawa T, et al. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep 2010;23:1317-1323.
6. Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012;42:368-375.
7. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007;37 Suppl 2:S95-S100.
8. Hatanaka K, Kudo M, Fukunaga T, et al. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology 2007;50:24-31.
9. El- Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.
10. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011;9: 617-623.
11. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.
12. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol 2003;38:954-961.
13. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL; Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22:788-793.
14. Okanoue T, Umemura A, Yasui, K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol 2011;26 Suppl 1:153-162.
15. Eguchi Y, Hyogo H, Ono M, et al. JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study. J Gastroenterol 2012;47:586-595.
16. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-1719.
17. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755.
18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
19. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
20. Starley BQ, Calcagno CJ., Harrison S A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-1832.
21. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010;16:1436-1441.
22. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
23. Al-Abed Y, Kapurniotu A, Bucala R. Advanced glycation end products: Detection and reversal. Methods Enzymol 1999;309:152-172.
24. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101.
25. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-10026.
26. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344:109-116.
27. Yamagishi S, Maeda S, Matsui T, Ueda, S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012;1820:663-671.
28. Hyogo H, Yamagishi S, Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008, 14, 969-972.
29. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-1119.
30. Hayashi N, George J, Takeuchi M, et al. Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. PLoS One 2013;8:e70034.
31. Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012:18:1781-1788.
32. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011;12:2096-2102.
33. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008;14:973-978.
34. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-945.
35. Takeda A, A Japanese study group for alcoholic liver disease. A new diagnostic criteria of alcoholic liver disease. Kanzo 1993;34:888-896.
36. The world medical association, inc. Declaration of Helsinki; Ethical principle for medical research involving human subject. WMA General Assembly, Seoul, Korea, October 2008.
37. Iwamoto K, Kanno K, Hyogo H, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008;43:298-304.
38. Sakuraoka Y, Sawada T, Okada T, et al. MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 2010;16:5334-5341.
39. Guiu B, Deschamps F, Boulin M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: External validation. Cardiovasc Intervent Radiol 2012;35:1102-1108.
40. Zhang JB, Chen Y, Zhang B, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011;23:787-793.
41. Ju MJ, Qiu SJ, Fan J, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol 2009;44:635-642.
42. Morsi MI, Hussein AE, Mostafa M, El-Abd E, El-Moneim NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 2006;63:74-78.
43. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:4.